Finnish Heart Research Technology VTT's Method Eases Early Diagnosis of Severe Heart Muscle Disease

Dilated cardiomyopathy, a heart muscle disease leading to dilation and impaired contraction of the left ventricle, is a severe and often familial disease. It is difficult to diagnose the disease with cardiac ultrasound, particularly at an early stage when there are only minimal, early changes of the heart. VTT Technical Research Centre of Finland has developed a method based on cardiac MRI, currently in research use, to help the physician to identify disease-related changes of the heart at an early stage.

In dilated cardiomyopathy, the heart dilates and impaired contraction of the left ventricle leads to heart failure. The disease may be suspected based on symptoms and an enlarged cardiac shadow revealed in a chest x-ray, for example. The diagnosis is typically verified by cardiac ultrasound examination. At an early stage, minimal changes of the heart are difficult to observe with ultrasound because their distinction from normal variation can challenge even an experienced cardiologist.

The method developed during VTT's co-operation project utilises database data on variations in cardiac muscle measured with MRI scans taken from different projections. Cardiac MRIs of the patient are compared with database data on normal variation in healthy hearts, and with disease-related variation in healthy and sick hearts. This corresponds to the knowledge of an experienced physician on the appearance of cardiac MRI images and their deviations. With the help of this method developed by VTT, the essential information for diagnosis is easily available for all physicians regardless of their experience in interpreting cardiac MRIs.

Measurement values have been identified with the help of MRI to enable diagnosis at a very early stage of the disease. The key issue of the method is to develop a new visualisation technique, which enables presentation of essential information from a very large measurement set in an easily interpretable form. In addition, this research has developed a disease index representing the severity of disease, which offers a simple method for monitoring the disease and its treatment, for example.

The developed methods will be first applied, in a research context, to research and analysis of changes produced by various diseases and disease mechanisms. Later the goal is to provide a method for clinical use to assist physicians in diagnosing. The research will be explored further by applying the methods in the research of other heart and brain diseases. In addition to imaging data, the analysis method will include cell metabolism data acquired from blood samples, for example.

Information on dilated cardiomyopathy
Dilated cardiomyopathy is a severe heart disease, which causes dilation of the myocardium and is familial in as many as one third of cases. Because of this, it is recommended that the first-degree family members of the patient, even those with no symptoms, be examined to identify potential evidence of incipient disease. To organise monitoring and treatment, it is vital to identify as reliably as possible all of those, including the symptomless, who will later be at risk of developing the disease. In some cases, those at risk of developing the disease can be identified with DNA analysis.

A diseased myocardium can not be healed but the symptoms can be greatly alleviated with heart failure medication. Incidence of the disease in the adult population is approximately 36.5/100,000 and markedly lower among children. In Finland, dilated cardiomyopathy is the leading cause for heart transplantation and causes a considerable amount of morbidity and premature mortality among the working population.

Partners of the research are VTT Technical Research Centre of Finland, the Hospital District of Helsinki and Uusimaa (HUS), the Kuopio University Hospital (KYS) and the University of Kuopio.

About VTT Technical Research Centre of Finland
VTT Technical Research Centre of Finland is the biggest contract research organization in Northern Europe. VTT provides high-end technology solutions and innovation services. From its wide knowledge base, VTT can combine different technologies, create new innovations and a substantial range of world-class technologies and applied research services, thus improving its clients' competitiveness and competence. Through its international scientific and technology network, VTT can produce information, upgrade technology knowledge and create business intelligence and value added to its stakeholders. For further information, please visit http://www.vtt.fi.

Most Popular Now

MEDICA 2024 + COMPAMED 2024: Adapted Hal…

11 - 14 November 2024, Düsseldorf, Germany. The final preparations for MEDICA 2024 and COMPAMED 2024 in Düsseldorf have begun. A total of more than 5,500 exhibitors from approximately 70 countries...

AI does Not Necessarily Lead to more Eff…

The use of artificial intelligence (AI) in hospitals and patient care is steadily increasing. Especially in specialist areas with a high proportion of imaging, such as radiology, AI has long...

Commission Joins Forces with Venture Cap…

The Commission has launched a Trusted Investors Network bringing together a group of investors ready to co-invest in innovative deep-tech companies in Europe together with the EU. The Union's investment...

Why the NHS is Seeking to Make Media Ser…

Opinion Article by Dean Moody, Healthcare Services Director, Airwave Healthcare. Tim Kelsey and Martha Lane Fox called for WiFi to be made available free of charge throughout the NHS back in...

An AI-Powered Pipeline for Personalized …

Ludwig Cancer Research scientists have developed a full, start-to-finish computational pipeline that integrates multiple molecular and genetic analyses of tumors and the specific molecular targets of T cells and harnesses...

Philips and Medtronic Advocacy Partnersh…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke...

Wearable Cameras Allow AI to Detect Medi…

A team of researchers says it has developed the first wearable camera system that, with the help of artificial intelligence (AI), detects potential errors in medication delivery. In a test whose...

AI could Transform How Hospitals Produce…

A pilot study led by researchers at University of California San Diego School of Medicine found that advanced artificial intelligence (AI) could potentially lead to easier, faster and more efficient...

New AI Tool Predicts Protein-Protein Int…

Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication. The computational tool...

AI for Real-Rime, Patient-Focused Insigh…

A picture may be worth a thousand words, but still... they both have a lot of work to do to catch up to BiomedGPT. Covered recently in the prestigious journal Nature...

Start-Ups will Once Again Have a Starrin…

11 - 14 November 2024, Düsseldorf, Germany. The finalists in the 16th Healthcare Innovation World Cup and the 13th MEDICA START-UP COMPETITION have advanced from around 550 candidates based in 62...

G-Cloud 14 Makes it Easier for NHS to Bu…

NHS organisations will be able to save valuable time and resource in the procurement of technologies that can make a significant difference to patient experience, in the latest iteration of...